- Subscribe to my blog via RSS
- Connect with me on LinkedIn
- Connect with me on Facebook
- Follow me on Twitter
Listen to internet radio with RemissionMan on Blog Talk Radio
Archives
- October 2022
- April 2022
- March 2022
- February 2022
- December 2021
- July 2021
- June 2021
- May 2021
- November 2020
- September 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- December 2008
- October 2008
- July 2008
- June 2008
- May 2008
- September 2007
- August 2007
- April 2007
- January 2007
Categories
Tags
50 fit tips bendeka be well philly big climb philly blood cancer brad schoener cancer cancer survivors chemotherapy chesapeakeman chronic lymphocytic leukemia cll crozer keystone cycling endurance sports expo ethan zohn ford ironman world championship grassroot soccer headstrong foundation ing nyc marathon ironman leukemia & lymphoma society liberty sports magazine Lls man of the year marathon motivation nyc marathon Philadelphia Insurance Triathlon philadelphia magazine philadelphia marathon philly health watch racing racing for reasons racing for recovery remission remissionman rituxan running survivor team in training training triathlon two oceans ultra marathon world triathlon corporation-
Recent Comments
- Robert A Mina on Cancer’s Give and Take
- M.L. Sicoli on Cancer’s Give and Take
- Joseph Romano on Cabrini University Healing Mass
- Jim Vail on Cabrini University Healing Mass
- Steve on Funk #9 & All Things Must Pass
New Drug May Be Best Treatment for Leukemia Yet
(TIME.com) — It’s called ibrutinib, and it’s a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy.
In research published in the New England Journal of Medicine (NEJM), scientists report that the experimental drug, which differs from broadly acting chemotherapy agents by specifically targeting certain cancer-causing processes, significantly prolongs the life of patients.
Ibrutinib is currently being tested on tumors that target the body’s immune system, such as CLL and mantle cell lymphoma (MCL).
CLL is the second most common form of leukemia among adults in the U.S., and about 15,000 Americans, most of whom are elderly, are diagnosed with the blood and bone marrow cancer every year.
Once ibrutinib binds to the immune system’s B-cells, it prevents tumors growing in these cells from signaling for the nutrients they need to grow and divide. According to the study, the drug doesn’t seem to affect the body’s T-cells, as chemotherapy agents do, so patients experience fewer side effects.
Early work on animals showed that the experimental drug effectively shut down tumor cell division, so the researchers tested the compound on 85 CLL patients who had all tried and failed to respond to at least two other anti-cancer treatments. Some even harbored genetic mutations associated with particularly aggressive forms of CLL that typically lead to death within two years of diagnosis.
The patients were randomized to take one of two different doses of an ibrutinib pill a day. After nearly two years of treatment, 71% of this hard-to-treat group had responded with slower tumor growth, and at 26 months, 75% showed no additional progression of their cancer. At the end of the study period, 83% of the participants were still alive, and most of the patients only complained of diarrhea and fatigue.
“This is truly a breakthrough drug for CLL. I have been a CLL specialist since 1997, and we have not had a drug like this come into the field yet,” says study author Dr. John C. Byrd, the director of the division of hematology at The Ohio State University Comprehensive Cancer Center.
“The most common thing I have heard patients say is that it brings their disease under control and makes them feel how they did before their cancer. I’ve heard that at least a dozen times.”
The scientists and patients were most encouraged by the fact that the the drug helped them to enjoy a longer period of time, on average, in which their tumors remained stable and didn’t progress, than they they had while using chemotherapy agents.
The MCL patients showed similarly positive results. MCL is an aggressive form of non-Hodgkin lymphoma that generally doesn’t respond to existing chemotherpay, immune-based treatment or stem cell transplants.
But in a separate study also appearing in NEJM involving 111 advanced MCL patients, about 68% of the participants responded to ibrutinib and 58% were alive after 18 months on the therapy. The response rate was encouraging since the last agent to treat MCL was approved by the Food and Drug Administration (FDA) with a 30% response rate.
That efficacy data, combined with the experimental drug’s favorable side effect profile, has some doctors hoping that ibrutinib might one day replace the harsher chemotherapy agents that are currently the standard of care for these cancers.
“With chemotherapy, you get it for a specific period of time because patients cannot tolerate the side effects long term. This is an oral medicine that targets something the leukemia cells are dependent on but the rest of the body isn’t,” says Byrd.
“People can take a pill once a day and generally they tolerate it well. The side effects are much less than the chemo or other therapies that would be used in this setting.”
Ibutrinib is the first agent to specifically target the BTK pathway, but it’s part of a wave of new anti-cancer agents that have been developed to act as more precise, smart bomb medications that destroy just cancer cells while leaving healthy cells intact. That allows them to minimize the often intolerable side effects of harsher drugs like chemotherapy agents, which tend to wipe out both healthy and cancerous cells at once.
“In some situations there have been some medications we have tested where patients have said they would rather not be treated and pass (away) from their leukemia than go through the side effects of their medicine that is not going to cure them,” says Byrd.
Both of the clinical trials, which were sponsored by ibrutinib’s developer, Pharmacyclics, involved older adults, who are most often affected by these cancers, so the researchers believe the results should be applicable to most patients diagnosed with these diseases.
The studies also suggest that patients may benefit from longer progression-free survival if they start therapy earlier in the course of their disease.
“Right now, after this drug gets approved, it will likely be used in the setting of relapse initially, but there are ongoing studies that are looking at it for initial therapy. It is something that is especially (beneficial) for elderly patients who do not tolerate chemotherapy well. This will likely replace chemotherapy,” says Bryd.
The fact that even patients with the most aggressive types of CLL, which are driven by genetic mutations, responded to ibrutinib also hints that the experimental drug may become an important part of treating these cancers in coming years.
The FDA designated it as breakthrough therapy, and Pharmacyclics and Janssen, who are jointly developing the drug, plan to file a New Drug Application (NDA) with the FDA for the use of ibrutinib to treat B-cell malignancies by 2014.
VIDEO CLIP
This article intially published on TIME.com.